Skip to main content

Table 1 Demographic and baseline clinical characteristics

From: Immuno-priming durvalumab with bevacizumab in HER2-negative advanced breast cancer: a pilot clinical trial

Characteristic

Value

Age (median, range)

54.1 (34.5–77.4)

Tumor subtype

 Hormone-positive

16 (64%)

 TNBC

9 (36%)

Histology

 Ductal

18 (72%)

 Lobular

4 (16%)

 Other

3 (12%)

Time (months) from diagnosis of metastatic disease (median, range)

18.1 (2–116)

Time (months) receiving bevacizumab before registration (median, range)

8.4 (1.6–24.7)

Number of previous treatment lines for metastatic disease

 1

3 (12%)

 2

9 (36%)

 3

3 (12%)

 4

7 (28%)

 5

2 (8%)

 7

1 (4%)

Companion drug in the pre-trial regimen:

 Capecitabine

13 (52%)

 Paclitaxel

10 (40%)

 Docetaxel

1 (4%)

 Cisplatin

1 (4%)

ECOG 0

15 (60%

ECOG 1

10 (40%)

PD-L1 expression:

 Positive (> 1%)

4 (16%)

 Negative (0%)

16 (64%)

 Unknown

5 (20%)